|Summary sheet: Methaqualone|
|Common names||Methaqualone, Quaaludes, "Ludes", Mandrax, Sopor|
|Routes of Administration|
Methaqualone (brand name Quaalude in the US and Mandrax in the UK) is a central nervous system (CNS) depressant of the quinazolinone class that acts as a sedative and hypnotic. The sedative–hypnotic activity of methaqualone was first noted by researchers in the 1950s and in 1962 methaqualone itself was patented in the US by Wallace and Tiernan. Its use peaked in the early 1970s as a hypnotic, for the treatment of insomnia, and as a sedative and muscle relaxant. It is still produced and used clandestinely as a recreational drug throughout the world. The drug was popular in the 1970s with hippies and in the disco club scene.
Methaqualone, or 2-methyl-3-(2-methylphenyl)-4(3H)-quinazolinone, is a compound of the quinazolinone class. Quinazolinone is a bicyclic structure containing a phenyl ring bound to another six-membered ring with two nitrogen members and a ketone group bound to R4. In methaqualone, this structure is substituted at R2 with a methyl group. Additionally, methaqualone contains a phenyl ring with a methyl group bound to R2 which is attached to the quinazolinone structure at R3.
Methaqualone is also known as 3,4-dihydro-2-methyl-4-oxo-3-o-tolylquinazoline, 2-methyl-3-(2-methylphenyl)-4-(3H)-quinazolinone, Metholquizolone, QZ-2, 2-Methyl-3-o-tolyl-4(3H)-quinazolinone, RIC-272, TR-495 and Quaalude. The Methaqualone LD50 for mice is 1250 mg/kg, and for rats both the values 255 and 326 mg/kg has been published. A common human dose (as sedative) is 150 mg for a 75 kg person.
Despite prior speculation, a 2015 study demonstrates that methaqualone exhibits distinct functional properties at the GABA receptor sites compared with other allosteric modulators, and it mediates these through a different mechanism than the barbiturates and benzodiazepines that it historically has been lumped together with. These distinctions could contribute to the reported differences in the in vivo effects induced by methaqualone and classic CNS depressants. In any case, the multifaceted functionality of methaqualone at GABAA receptors seems to be at the root of its clinical efficacy, as well as the addiction liability and recreational use associated with the drug.
Methaqualone is a member of the class of quinazolines that is quinazolin-4-one substituted at positions 2 and 3 by methyl and o-tolyl groups respectively. A depressant that increases the activity of the GABA receptors in the brain and nervous system, it is used as a sedative and hypnotic medication. It has a role as a GABA agonist and a sedative.
It could be speculated that despite differences in targeted receptors, methaqualone essentially produces a variety of effects by binding to its receptor sites and magnifying the efficiency and effects of the neurotransmitter gamma aminobutyric acid (GABA) by acting on its receptors. As this site is the most prolific inhibitory receptor set within the brain, its modulation would explain the resulting sedating or calming effects which ensue.
Although some early research indicated it may operate at the benzodiazepine receptor site, this doesn’t appear to be the case. More recent evaluations have pointed to a different GABAA modulatory site located on the transmembrane b(+)/a(-) subunit interface.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), a research literature based on collected anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be regarded with a healthy degree of skepticism. It is worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce a full spectrum of effects. Likewise, adverse effects become much more likely with higher doses and may include addiction, serious injury, or death ☠.
- Sedation - In terms of energy level alterations, this drug is extremely sedating and often results in an overwhelmingly lethargic state. At higher levels, this causes users to suddenly feel as if they are extremely sleep deprived and have not slept for days, forcing them to sit down and generally feel as if they are constantly on the verge of passing out instead of engaging in physical activities. This sense of sleep deprivation increases proportional to dosage and eventually becomes powerful enough to force a person into complete unconsciousness.
- Physical euphoria - This compound is unusually euphoric in comparison to other compounds within the same class.
- Muscle relaxation
- Motor control loss
- Respiratory depression
- Changes in felt gravity
The visual effects of methaqualone are unusually strong for other depressants of its class. They can be broken down into several components which progressively intensify proportional to dosage.
- Visual acuity suppression
- Double vision
- Visual disconnection - A sense of subtle disconnection from visual input is often experienced with high dosage methaqualone.
- Internal hallucination - The internal hallucinations of methaqualone can be described as more solid than psychedelics and do not seem to be composed of visual geometry. The most common way in which they manifest themselves are through hypnagogic scenarios. They are most common during high dosages and can be comprehensively described through their variations as lucid in believability, fixed in style, autonomous in controllability, and equal in new experiences and memory replays in content.
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
Overdose of methaqualone can lead to seizures, coma or death. Taking doses of over 300mg can be dangerous for first time users. Depending on the state of the user's individual tolerance, doses of about 8,000mg per day can be fatal whilst others on even higher doses (of up to 20,000mg) may survive.
Although the exact lethal dosage of methaqualone has not been formally established, like many depressants, it is safe at appropriate dosages. Complications may arise when administered in excess or in combination with other depressants.
It is strongly recommended that one use harm reduction practices when using this substance.
Quaaludes that are sold only for illicit recreational use now are synthesized in illegal laboratories. Illegally produced Quaaludes can contain other central nervous system depressants such as benzodiazepines or even fentanyl.
Tolerance and addiction potential
Methaqualone is extremely addictive. Tolerance to the sedative-hypnotic effects develops within a couple of days of repeated administration. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). Methaqualone presents cross-tolerance with all gabaergic depressants, meaning that after the consumption of methaqualone all compounds of the same class will have a reduced effect.
Abrupt discontinuation of methaqualone following regular dosing over several days can result in a withdrawal phase which includes rebound symptoms such as increased anxiety and insomnia. It is possible to gradually reduce the dose over the course of several days, which will lengthen the duration of the withdrawal period but reduce the perceived intensity.
Although many psychoactive substances are reasonably safe to use on their own, they can suddenly become dangerous or even life-threatening when combined with other substances. The following list includes some known dangerous combinations (although it is not guaranteed to include all of them). Independent research (e.g. Google, DuckDuckGo) should always be conducted to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
- Depressants (1,4-Butanediol, 2M2B, alcohol, benzodiazepines, barbiturates, GHB/GBL, methaqualone, opioids) - This combination potentiates the muscle relaxation, amnesia, sedation, and respiratory depression caused by one another. At higher doses, it can lead to a sudden, unexpected loss of consciousness along with a dangerous amount of depressed respiration. There is also an increased risk of suffocating on one's vomit while unconscious. If nausea or vomiting occurs before a loss of consciousness, users should attempt to fall asleep in the recovery position or have a friend move them into it.
- Stimulants - It can be dangerous to combine depressants with stimulants due to the risk of accidental excessive intoxication. Stimulants mask the sedative effect of depressants, which is the main factor most people use to gauge their level of intoxication. Once the stimulant effects wear off, the effects of the depressant will significantly increase, leading to intensified disinhibition, motor control loss, and dangerous black-out states. This combination can also potentially result in severe dehydration if one's fluid intake is not closely monitored. If choosing to combine these substances, one should strictly limit themselves to a pre-set schedule of dosing only a certain amount per hour until a maximum threshold has been reached.
- Dissociatives - This combination can unpredictably potentiate the amnesia, sedation, motor control loss and delusions that can be caused by each other. It may also result in a sudden loss of consciousness accompanied by a dangerous degree of respiratory depression. If nausea or vomiting occurs before consciousness is lost, users should attempt to fall asleep in the recovery position or have a friend move them into it.
- Australia: Methaqualone is Schedule 9 in Australia, meaning it is illegal without a license and deemed to have no medical value.
- Austria: Methaqualone is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).
- Canada: Methaqualone is Schedule III in Canada, meaning it requires a prescription or license to legally possess.
- Germany: Methaqualone is controlled under BtMG Anlage II, making it illegal to manufacture, import, possess, sell, or transfer it without a license.
- Switzerland: Methaqualone is a controlled substance specifically named under Verzeichnis A. Medicinal use is permitted.
- United Kingdom: Methaqualone is a Class B drug.
- United States: Methaqualone is a Schedule I drug, and is illegal to possess without a license.
- Methaqualone (Wikipedia)
- Methaqualone (Erowid Vault)
- Methaqualone (Isomer Design)
- Quaaludes (Drugs.com)
- Risks of Combining Depressants (Tripsit) | https://tripsit.me/combining-depressants/
- US Patent 3135659 – Hydroxy and Alkoxy Aryl Quinazolones
- A Multifaceted GABAA Receptor Modulator: Functional Properties and Mechanism of Action of the Sedative-Hypnotic and Recreational Drug Methaqualone (Quaalude) (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/26056160
- "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.